LU91112I2 - Pregabalin, facultativement sous forme d'un sel pharmaceutiquement acceptable. - Google Patents

Pregabalin, facultativement sous forme d'un sel pharmaceutiquement acceptable.

Info

Publication number
LU91112I2
LU91112I2 LU91112C LU91112C LU91112I2 LU 91112 I2 LU91112 I2 LU 91112I2 LU 91112 C LU91112 C LU 91112C LU 91112 C LU91112 C LU 91112C LU 91112 I2 LU91112 I2 LU 91112I2
Authority
LU
Luxembourg
Prior art keywords
pregabalin
optionally
pharmaceutically acceptable
acceptable salt
compound
Prior art date
Application number
LU91112C
Other languages
English (en)
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25388336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91112(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of LU91112I2 publication Critical patent/LU91112I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/12—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
LU91112C 1992-05-20 2004-10-06 Pregabalin, facultativement sous forme d'un sel pharmaceutiquement acceptable. LU91112I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88608092A 1992-05-20 1992-05-20
PCT/US1993/004680 WO1993023383A1 (fr) 1992-05-20 1993-05-18 Analogues de gaba et d'acide l-glutamique pour le traitement de maladies du systeme nerveux central

Publications (1)

Publication Number Publication Date
LU91112I2 true LU91112I2 (fr) 2004-12-06

Family

ID=25388336

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91112C LU91112I2 (fr) 1992-05-20 2004-10-06 Pregabalin, facultativement sous forme d'un sel pharmaceutiquement acceptable.

Country Status (21)

Country Link
EP (1) EP0641330B1 (fr)
JP (2) JP3856816B2 (fr)
KR (1) KR950701625A (fr)
AT (1) ATE207052T1 (fr)
AU (1) AU677008B2 (fr)
CA (1) CA2134674C (fr)
CZ (1) CZ286106B6 (fr)
DE (2) DE122004000039I2 (fr)
DK (1) DK0641330T3 (fr)
ES (1) ES2165857T3 (fr)
FI (1) FI945426L (fr)
HU (2) HU222776B1 (fr)
LU (1) LU91112I2 (fr)
NL (1) NL300164I2 (fr)
NO (1) NO944370L (fr)
NZ (1) NZ253459A (fr)
PT (1) PT641330E (fr)
RU (2) RU94046105A (fr)
SG (1) SG48288A1 (fr)
SK (1) SK283281B6 (fr)
WO (1) WO1993023383A1 (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113052A0 (en) * 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
AU703428B2 (en) * 1994-07-27 1999-03-25 Warner-Lambert Company Use of gabapentin in the treatment of anxiety and panic
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5616793A (en) * 1995-06-02 1997-04-01 Warner-Lambert Company Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) * 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
WO1998017627A1 (fr) * 1996-10-23 1998-04-30 Warner-Lambert Company Acides aminobutyriques gamma substitues utilises comme agents pharmaceutiques
WO1999008670A1 (fr) * 1997-08-20 1999-02-25 Guglietta, Antonio Analogues de gaba utilises pour prevenir et traiter des lesions gastro-intestinales
JP3782935B2 (ja) 1997-09-08 2006-06-07 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 抗癲癇化合物を含有する鎮痛剤組成物およびその使用方法
CA2327285C (fr) * 1998-05-15 2005-06-14 Warner-Lambert Company Preparations pharmaceutiques stabilisees de derives d'acide gamma-aminobutyrique et procede de fabrication associe
EP1121114B1 (fr) * 1998-10-16 2007-01-10 Warner-Lambert Company Llc Utilisation d'analogues du gaba pour la preparation d'un medicament pour le traitement de la manie et des troubles bipolaires
AU1602100A (en) 1998-11-25 2000-06-13 Warner-Lambert Company Improved gamma amino butyric acid analogs
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
HUP0200738A3 (en) * 1999-04-08 2003-03-28 Warner Lambert Co Method of the treatment of incontinence
RS50352B (sr) * 1999-06-10 2009-11-10 Warner-Lambert Company Llc., Monosupstituisane 3-propil gama-aminobuterne kiseline
US6642398B2 (en) 1999-06-10 2003-11-04 Warner-Lambert Company Mono-and disubstituted 3-propyl gamma-aminobutyric acids
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
AU2002213422A1 (en) 2000-09-13 2002-03-26 Georgetown University Synthesis of 2-hydroxymethylglutamic acid and congeners thereof
AU2002230398A1 (en) 2000-10-06 2002-04-29 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
AU2002211863A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
RU2202538C2 (ru) * 2001-05-04 2003-04-20 Савельев Евгений Александрович Способ получения 4-аминомасляной кислоты
US6462084B1 (en) * 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
AU2002345638A1 (en) 2001-06-11 2002-12-23 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CA2449729C (fr) 2001-06-11 2009-11-03 Xenoport, Inc. Promedicaments d'analogues de gaba, compositions et utilisations desdits promedicaments
AU2002316231A1 (en) 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
RU2220131C2 (ru) * 2002-02-28 2003-12-27 Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" Соли 4-амино-3-фенилбутановой кислоты и лекарственное средство, обладающие антиишемической гипотензивной, противоаритмической, ноотропной и антигипоксической активностью
AU2003222033A1 (en) 2002-03-20 2003-10-08 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
US20030225149A1 (en) * 2002-04-30 2003-12-04 Blazecka Peter G. Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids
AU2003243180A1 (en) 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7071339B2 (en) 2002-08-29 2006-07-04 Warner Lambert Company Llc Process for preparing functionalized γ-butyrolactones from mucohalic acid
US7060727B2 (en) 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
AU2003303041B2 (en) 2002-12-13 2008-07-24 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
NZ540591A (en) 2002-12-13 2008-03-28 Warner Lambert Co Pregabalin derivatives for the treatment of fibromyalgia and other disorders
CA2451267A1 (fr) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Utilisations pharmaceutiques de ligands alpha2delta
KR20060119971A (ko) 2003-09-11 2006-11-24 제노포트 인코포레이티드 Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
AU2004271800A1 (en) 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
NZ579515A (en) 2003-09-17 2011-09-30 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs
SG147437A1 (en) 2003-10-14 2008-11-28 Xenoport Inc Crystalline form of gamma-aminobutyric acid analog
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
MX2007005306A (es) 2004-11-04 2007-06-11 Xenoport Inc Formas de dosis oral de liberacion sostenida de la prodroga gabapentina.
EP1820502A1 (fr) 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Combinaisons de principes actifs comprenant de dérivés d' azolylcarbinol
CA2673545A1 (fr) 2006-12-22 2008-07-03 Recordati Ireland Limited Therapie combinee de troubles du tractus urinaire inferieur a l'aide de ligands de l'.alpha.2.delta. et d'ains
CN101965328A (zh) * 2007-12-26 2011-02-02 基因里克斯(英国)有限公司 普瑞巴林的制备方法
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
ES2601852T3 (es) 2008-01-25 2017-02-16 Xenoport, Inc. Forma cristalina de sales de calcio de ácidos (3S)-aminometil-5-metil-hexanoicos y métodos de uso
EP2250148B1 (fr) 2008-01-25 2016-08-17 XenoPort, Inc. Forme cristalline de sels de calcium d'acide (3s)-aminomethyl-5-methyl-hexanoique et ses procedes d'utilisation
EP2110372A1 (fr) 2008-04-16 2009-10-21 Chemo Ibérica, S.A. Intermédiaires pour la préparation de prégabaline et leur procédé de préparation
EP2116539A1 (fr) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles en tant que ligands améliorant les effets analgésiques des opioïdes et réduisant leur dépendance
EP2123626A1 (fr) 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-cristaux de duloxétine et générateurs de co-cristaux pour le traitement de la douleur
ES2589915T3 (es) 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
RU2393855C1 (ru) * 2008-12-29 2010-07-10 Общество С Ограниченной Ответственностью "Валента-Интеллект" Средство, обладающее анксиолитической и церебропротекторной активностью, уменьшающее влечение к алкоголю
ES2362913B1 (es) 2009-12-24 2012-05-24 Moehs Iberica S.L. Nuevo método para la preparación de (s)-pregabalina.
EP2353598A1 (fr) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour utilisation dans la prévention et/ou le traitement de la douleur post-opératoire
EP2353591A1 (fr) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la potentialisation de l'effet analgésique d'opioïdes et d'opiacés dans la douleur post-opératoire et en atténuant la dépendance
EP2548871B1 (fr) 2010-03-18 2017-07-19 Daiichi Sankyo Company, Limited Dérivé d'imidazole substitué par cycloalkyle
BR112012023412A2 (pt) 2010-03-18 2018-05-08 Daiichi Sankyo Company, Limited composto, drogra farmacêutica, inibidor de tafia, promotor de fibrinólise, droga preventiva ou terapêutica, composição farmacêutica, e, uso de um composto.
EP2383255A1 (fr) 2010-04-28 2011-11-02 Lacer, S.A. Nouveaux composés, synthèse et utilisation dans le traitement de la douleur
EP2388005A1 (fr) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la prévention et/ou le traitement du vomissement induit par la chimiothérapie ou la radiothérapie
CA2805371C (fr) 2010-07-30 2017-10-31 Toray Industries, Inc. Agent therapeutique ou prophylactique pour douleur neuropathique
EP2415471A1 (fr) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma dans l'hyperalgie induite par opioïdes
EP2415460A1 (fr) 2010-08-03 2012-02-08 ratiopharm GmbH Formulations pour l'administration orale de prégabaline
US8212072B2 (en) 2010-08-13 2012-07-03 Divi's Laboratories, Ltd. Process for the preparation of pregabalin
EP2524694A1 (fr) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma dans la douleur liée au diabète de type 2
EP2527319A1 (fr) 2011-05-24 2012-11-28 Laboratorios Del. Dr. Esteve, S.A. Formes cristallines de prégabaline et co-formateurs pour le traitement de la douleur
WO2013100873A1 (fr) 2011-12-19 2013-07-04 Mahmut Bilgic Formulation pharmaceutique de prégabaline (taille de particules 300-2500 micromètres)
ES2423254B1 (es) 2012-02-15 2014-03-26 Laboratec, S.L. Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
CA2903000C (fr) 2013-01-28 2021-10-12 Hector L. Lopez Procedes d'amelioration de la tolerance a ?-alanine, de sa pharmacodynamie et de son efficacite et son utilisation
TN2016000228A1 (en) 2013-12-17 2017-10-06 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS.
AU2014364644A1 (en) 2013-12-17 2016-06-23 Laboratorios Del Dr. Esteve, S.A. Gabapentinoids and Sigma receptor ligands combinations
WO2016075082A1 (fr) 2014-11-10 2016-05-19 Sandoz Ag Amination réductrice stéréosélective d'aldéhydes alpha-chiraux au moyen d'ω-transaminases pour la synthèse de précurseurs de la prégabaline et du brivaracétam
CA3099775A1 (fr) 2018-05-14 2019-11-21 Xgene Pharmaceutical Inc. Procede de fabrication de conjugues de carbamate de 1-(acyloxy)alkyle de naproxene et de pregabaline
DE202018105573U1 (de) 2018-09-27 2018-10-19 Laboratec Pharmazeutische Zusammensetzung zur Behandlung der Harninkontinenz und Enuresis
HU231397B1 (hu) 2021-01-22 2023-06-28 Egis Gyógyszergyár Zrt. Pregabalint tartalmazó topikális gyógyszerkészítmény
WO2022157525A1 (fr) 2021-01-22 2022-07-28 Egis Gyógyszergyár Zrt. Formulation topique contenant des composés phospholipides modifiés

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4840460B1 (fr) * 1969-02-05 1973-11-30
US4173541A (en) * 1978-06-05 1979-11-06 Cincinnati Milacron Chemicals Inc. Polynuclear hindered phenols and stabilized organic materials containing the phenols
US4322440A (en) * 1980-06-25 1982-03-30 New York University Anticonvulsive compositions and method of treating convulsive disorders
US4479005A (en) * 1982-12-16 1984-10-23 The Dow Chemical Company Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids
US4771038A (en) * 1986-01-21 1988-09-13 Ici Americas Inc. Hydroxamic acids
US4814342A (en) * 1986-10-31 1989-03-21 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
KR930003864B1 (ko) * 1990-10-19 1993-05-14 한국과학기술연구원 d-2-(6-메톡시-2-나프틸)-프로피온산의 제조방법
AU9137091A (en) * 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
US5198548A (en) * 1992-01-30 1993-03-30 Warner-Lambert Company Process for the preparation of D(-) and L(+)-3,3-diphenylalanine and D(-) and L(+)-substituted 3,3-diphenylalanines and derivatives thereof

Also Published As

Publication number Publication date
EP0641330B1 (fr) 2001-10-17
JP3856816B2 (ja) 2006-12-13
PT641330E (pt) 2002-03-28
JPH07508288A (ja) 1995-09-14
RU2140901C1 (ru) 1999-11-10
NL300164I1 (nl) 2005-01-03
WO1993023383A1 (fr) 1993-11-25
HU222776B1 (hu) 2003-10-28
HK1011022A1 (en) 1999-07-02
HU9403310D0 (en) 1995-02-28
DK0641330T3 (da) 2001-12-03
EP0641330A1 (fr) 1995-03-08
HU9702482D0 (en) 1998-03-02
NL300164I2 (nl) 2005-02-01
HU222339B1 (hu) 2003-06-28
EP0641330A4 (fr) 1997-05-28
DE122004000039I2 (de) 2006-06-29
ES2165857T3 (es) 2002-04-01
RU94046105A (ru) 1997-06-20
CZ284994A3 (en) 1995-03-15
JP4297814B2 (ja) 2009-07-15
FI945426A0 (fi) 1994-11-18
DE69330949T2 (de) 2002-04-04
SK139594A3 (en) 1995-05-10
KR950701625A (ko) 1995-04-28
AU4379493A (en) 1993-12-13
SK283281B6 (sk) 2003-05-02
ATE207052T1 (de) 2001-11-15
JP2004238398A (ja) 2004-08-26
CA2134674A1 (fr) 1993-11-25
DE69330949D1 (de) 2001-11-22
CZ286106B6 (cs) 2000-01-12
HUT71522A (en) 1995-12-28
NZ253459A (en) 1997-03-24
FI945426A7 (fi) 1994-11-18
AU677008B2 (en) 1997-04-10
NO944370L (no) 1994-11-21
NO944370D0 (no) 1994-11-16
SG48288A1 (en) 1998-04-17
DE122004000039I1 (de) 2006-05-18
FI945426L (fi) 1994-11-18
CA2134674C (fr) 2004-12-21

Similar Documents

Publication Publication Date Title
LU91112I2 (fr) Pregabalin, facultativement sous forme d'un sel pharmaceutiquement acceptable.
LU91406I2 (fr) Anidulafungine, optionnellement sous forme d'un sel pharmaceutiquement acceptable -ECALTA
IL127058A0 (en) Improved process for the synthesis of protected esters of (s)-3,4-dihydroxybutyric acid
SE8201854L (sv) N-substituerade amino-aminosyror
AU515774B2 (en) Benzopyran derivatives
KR960029333A (ko) 인돌피페리딘 유도체
KR880003958A (ko) 신규 세펨화합물 및 그의 제조방법
HUP9900851A2 (hu) Benzotiofénszármazékok felhasználása véredény simaizom sejtek migrálásának inhibiálására alkalmas gyógyszerkészítmények előállítására
CA2116617A1 (fr) Derives esculetine et composition pharmaceutique
ZA902649B (en) Heteroaryl-3-oxo-propanenitrile derivatives useful in the treatment of rheumatoid arthritis and other autoimmune diseases
ES2104509A1 (es) Nuevos compuestos derivados de 2-(3,4-disustituido-1-piperazinil)-5-fluoropirimidina.
PH22131A (en) 5-oxo-1-imidazolidine acetamido derivatives and process foro the preparation thereof
AU7892591A (en) Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof
ES8707518A1 (es) Un procedimiento para preparar nuevos derivados del 1,3-ben-zoxatiol
EP0555479A4 (fr)
EP0201349A3 (fr) Dérivés de tétrazole
IE873182L (en) Triazaspirodecanylmethylindolone derivatives
MY123317A (en) Synthesis of chiral beta-amino acids
ZA842423B (en) Compounds with antiinflammatory activity,process for preparation thereof and pharmaceutical compositions therefrom
MX9302970A (es) Analogos de acido l-glutamico y gaba para tratamiento anti-ataque.
TW353071B (en) Chromene compounds with neutroleptic activity, their preparation and pharmaceutical compositions
NO941757D0 (no) 1-fenylpyrrolidon-derivater med optisk aktivitet, mellomprodukter for fremstilling derav og fremgangsmåter for deres fremstilling
FI931580L (fi) Menetelmä terapeuttisesti aktiivisten tetratsolijohdannaisten valmistamiseksi
GEP19970937B (en) Method of producing derivatives of muramyldipeptide
UA6324A1 (uk) Спосіб одержання похідних 6-фтор-1, дігідро-4-оксо-7-заміщений піперазінілхінолін-3-карбонової кислоти або їх фармацевтично прийнятних солей